Utility of positron emission tomography scans in mantle cell lymphoma

American Journal of Hematology

Volumn 86, Issue 10, 2011, Pages 841-845

  Hosein, Peter J ^a   Pastorini, Vitor H ^a   Paes, Fabio M ^a   Eber, Daryl ^a   Chapman, Jennifer R ^b   Serafini, Aldo N ^a   Alizadeh, Ash A ^c   Lossos, Izidore S ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84860392642     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22126     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Fernàndez V, Hartmann E, Ott G, et al. Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005; 23: 6364-6369.
3. Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001; 13: 342-347.
4. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111: 2385-2387.
5. Garcia M, Romaguera JE, Inamdar KV, et al. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer 2009; 115: 1041-1048.
6. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197.
7. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
8. Lossos IS, Hosein PJ, Morgensztern D, et al. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. Leuk Lymphoma 2010; 51: 406-414.
9. Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144-4152.
10. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs event-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677-2684.
11. Geisler C, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in-vivo purged stem cell rescue: A non-randomized phase-2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
12. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511-518.
13. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27: 1209-1213.
14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
15. Hosein PJ, Lossos IS. The evolving role of 18F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma. Eur J Clin Med Oncol 2009; 2: 131-138.
16. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-3876.
17. Han HS, Escalón MP, Hsiao B, et al. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009; 20: 309-318.
18. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification. Cancer 2007; 110: 652-659.
19. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: A study of 766 patients. J Nucl Med 2010; 51: 25-30.
20. Gill S, Wolf M, Prince HM, et al. [18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 2008; 8: 159-165.
21. Brepoels L, Stroobants S, De Wever W, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008; 49: 1693-1701.
22. Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: A retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 2010; 37: 1633-1642.
23. Karam M, Ata A, Irish K, Feustel PJ, et al. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Commun 2009; 30: 770-778.
24. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571-578.
25. Collett D. Modelling Survival Data in Medical Research. London: Chapman & Hall; 1994. p 26.
26. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
27. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among medicare beneficiaries with cancer, 1999-2006. JAMA 2010; 303: 1625-1631.
28. Boellaard, R. Standards for PET Image acquisition and quantitative data analysis. J Nucl Med 2009; 50: 11s-20s.
29. Lockhart CM, MacDonald LR, Alessio AM, et al. Quantifying and reducing the effect of calibration error on variability of PET/CT standardized uptake value measurements. J Nucl Med 2011; 52: 218-224.
30. Cashen AF, Dehdashti F, Luo J, et al. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: Poor predictive value of international harmonization project interpretation. J Nucl Med 2011; 52: 386-392.
31. Spaepen K, Stroobants S, Dupont P et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: Does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003; 30: 682-688.
32. El-Galaly T, Prakash V, Christiansen I, et al. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: Status in a single center. Leuk Lymphoma 2011; 52: 597-603.
33. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL Intergroup Study. Blood 2010; 115: 3215-3223.